ABIOMED Inc

ABIOMED — Q1 2022 Earnings Presentation

9 slides from ABIOMED's earnings presentation, Aug 5, 2021

  1. Slide 1: Q1 FY 2022 Earnings Call

    ® Recovering Hearts. Saving Lives. Q1 FY 2022 Earnings Call Financial Results & Operational Highlights Recovering Hearts. Saving Lives.

  2. Slide 2: Financial Results, Q1 FY 2022

    2 FINANCIAL RESULTS, Q1 FY 2022 Fiscal Year ends March 31 Revenue ($M) & Growth Rates Cash* ($M) $848 $788 $805 $253 $736 $241 $232 $210 $597 $165 YOY -21% +2% +5% +17% +53% Q1'21 Q2'21 Q3'21 Q4'21 Q1'22 Q1'21 Q2'21 Q3'21 Q4'21 Q1'22 *No debt Gross Margin % Operating Margin % 81.5% 82.3% 82.1% 30.8%

  3. Slide 3: U.S. Utilization Mix, Q1 FY 2022

    3 U.S. UTILIZATION MIX, Q1 FY 2022 Revenue by Impella® Device Utilization by Indication Impella 5.0® / 5.5 (17%) Other Impella RP® (4%) (4%) Emergent (55%) Impella 2.5® (3%) ® Impella CP ® Protected PCI (76%) (41%) U.S. Hospital Site Penetration Patient Performance Revenue Performance Impella® Devic

  4. Slide 4: Abiomed FY 2022 Revenue Guidance

    4 ABIOMED FY 2022 REVENUE GUIDANCE Updated 8/4/2021 Abiomed FY’22 Abiomed FY’22 Prior Guidance Post-Q1 Guidance Revenue Revenue $990M - $1.03B $1.03B - $1.05B +17 - 22% YOY +22 - 24% YOY Operating Margin % Non-GAAP Operating Margin % 24 - 26% 24 - 26% FOR INVESTORS ONLY Recovering Hearts. Saving Liv

  5. Slide 5: Appendix

    5 APPENDIX FOR INVESTORS ONLY Recovering Hearts. Saving Lives.

  6. Slide 6: Impella RP with SmartAssist

    6 ® ® IMPELLA RP WITH SMARTASSIST AIC Console • Sensor technology providing real-time guidance and trends to help with pump management and weaning Mean PA pressure decreases • Designed for a simplified setup and insertion with Look for stable CVP EasyGuide lumen and improved case workflow PAPi incre

  7. Slide 7: Q1'22 GAAP to Non-GAAP Financial Walk

    7 Q1’22 GAAP TO NON-GAAP FINANCIAL WALK Non-GAAP Adjustments: 1. preCARDIA $115M IPR&D expense offset by $21M gain on prior investment 2. Shockwave after-tax gain of $13M 3. Excess tax benefits of $4M on stock-based compensation 4. Q1’21 non-GAAP financials reflect Shockwave after-tax gain of $18M a

  8. Slide 8: preCARDIA

    8 TM PRECARDIA Catheter-Mounted SVC Balloon Therapy System • Minimally invasive patented technology to rapidly treat Acutely Decompensated Heart Failure (ADHF) related volume overload by reducing preload in the right heart. • #1 cause of hospitalizations and length of stay in patients greater than 6

  9. Slide 9: Reassignment Defines Two Clinical Populations

    9 REASSIGNMENT DEFINES TWO CLINICAL POPULATIONS: INTEROPERATIVE & NON-INTRAOPERATIVE PROCEDURES LOWER ACUITY/MODERATE RESOURCES HIGHER ACUITY/ HIGHER RESOURCES HIGHEST ACUITY/ HIGHEST RESOURCES CATH PROCEDURES INTRAOPERATIVE NON-INTRAOPERATIVE • Single vessel disease DEVICE REMOVED AT END OF PROCEDU

ABIOMED — Q1 2022 Earnings Presentation on 6ix